Korro Bio, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Korro Bio, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $17.00K, a 90.12% decline year-over-year.
- Korro Bio, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $128.00K, a 82.42% decline year-over-year.
- Korro Bio, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $5.00K, a 97.09% decline year-over-year.
- Korro Bio, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $172.00K, a 23.74% increase year-over-year.
- Korro Bio, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $685.00K, a 65.23% decline from fiscal 2024.
- Korro Bio, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $1.97M, a 180.63% increase from fiscal 2023.
- Korro Bio, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $702.00K, a 1032.26% increase from fiscal 2022.
- Korro Bio, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $62.00K, a 95.22% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-03-31 | $17.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $685.00K 10-K · filed 2026-03-12 | |
| 2025-09-30 | $128.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $5.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $172.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $1.97M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $728.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $172.00K 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $139.00K 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $702.00K 10-K · filed 2025-03-18 | |
| 2023-09-30 | $228.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $82.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $51.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $62.00K 10-K · filed 2024-03-26 | |
| 2022-09-30 | -$1.00K 10-Q · filed 2022-11-08 | |
| 2021-12-31 | $110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $1.30M 10-K · filed 2023-03-10 |
| 2021-09-30 | $288.00K 10-Q · filed 2021-11-15 | $1.57M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-06-30 | $203.00K 10-Q · filed 2022-08-09 | $1.75M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $697.00K 10-Q · filed 2021-05-13 | $1.93M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-12-31 | $383.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $1.54M 10-K · filed 2022-03-15 |
| 2020-09-30 | $462.00K 10-Q · filed 2021-11-15 | $1.20M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $391.00K 10-Q · filed 2021-08-12 | $902.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $309.00K 10-Q · filed 2021-05-13 | $599.00K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $366.00K 10-K · filed 2021-03-29 |
| 2019-09-30 | $161.00K 10-Q · filed 2020-11-16 | $328.00K derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | $88.00K 10-Q · filed 2020-08-12 | $198.00K derived: sum of 4 quarters · filed 2020-08-12 |
| 2019-03-31 | $76.00K 10-Q · filed 2020-05-14 | |
| 2018-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $73.00K 10-K · filed 2020-03-26 |
| 2018-09-30 | $31.00K 10-Q · filed 2019-11-18 | |
| 2017-12-31 | $27.00K 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |